Respiratory Therapies Set to Drive Pharma Growth in Coming Months

Anti-diabetics and cardiac treatments are the main drivers of the domestic pharmaceutical market, with respiratory treatments projected to be the primary growth drivers in November, December, and January. With air pollution persisting, it is anticipated that the respiratory sector will continue to expand in the upcoming months.

Pharmarack's market research shows that the respiratory sector is worth ?16,413 crore, with a yearly growth rate of 12%. The value of anti-asthma and COPD products increased from ?6,094 crore in October 2021 to ?9,960 crore in October 2024. Similarly, the cough and cold market has increased in value from ?2,926 crore MAT to ?4,129 crore over the same period.

"The respiratory market shows the normal seasonal trend for the anti-asthma and cough and cold segment," said Sheetal Sapale, VP, commercial, Pharmarack. "There were fewer reported cases in October 2024 compared to October 2023, hence there is de-growth in the market. The market peaks in December and January and then gradually subsides as winter loses its intensity," Sapale said.

The combination of bad air quality and extreme cold is creating conditions perfect for sickness. Physicians explain that even after patients get better from the acute stage, the cough will continue for a few days to weeks.